The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:
Eric S Wohleb
Eric S Wohleb
The Ohio State University
United States
Alena Cristina Jaime-Ramirez
Alena Cristina Jaime-Ramirez
The Ohio State University
United States
Ji Young Yoo
Ji Young Yoo
Dardinger Laboratory for Neuro-oncology and Neurosciences
Columbus | United States
Luke Russell
Luke Russell
James Comprehensive Cancer Center
Jayson Hardcastle
Jayson Hardcastle
Mayo Clinic
United States
Samuel Dubin
Samuel Dubin
James Comprehensive Cancer Center
Columbus | United States

Clin Cancer Res 2015 Jul 31;21(14):3274-85. Epub 2015 Mar 31.

Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio.

Purpose: Oncolytic herpes simplex viruses (oHSV) represent a promising therapy for glioblastoma (GBM), but their clinical success has been limited. Early innate immune responses to viral infection reduce oHSV replication, tumor destruction, and efficacy. Here, we characterized the antiviral effects of macrophages and microglia on viral therapy for GBM.

Experimental Design: Quantitative flow cytometry of mice with intracranial gliomas (±oHSV) was used to examine macrophage/microglia infiltration and activation. In vitro coculture assays of infected glioma cells with microglia/macrophages were used to test their impact on oHSV replication. Macrophages from TNFα-knockout mice and blocking antibodies were used to evaluate the biologic effects of TNFα on virus replication. TNFα blocking antibodies were used to evaluate the impact of TNFα on oHSV therapy in vivo.

Results: Flow-cytometry analysis revealed a 7.9-fold increase in macrophage infiltration after virus treatment. Tumor-infiltrating macrophages/microglia were polarized toward a M1, proinflammatory phenotype, and they expressed high levels of CD86, MHCII, and Ly6C. Macrophages/microglia produced significant amounts of TNFα in response to infected glioma cells in vitro and in vivo. Using TNFα-blocking antibodies and macrophages derived from TNFα-knockout mice, we discovered TNFα-induced apoptosis in infected tumor cells and inhibited virus replication. Finally, we demonstrated the transient blockade of TNFα from the tumor microenvironment with TNFα-blocking antibodies significantly enhanced virus replication and survival in GBM intracranial tumors.

Conclusions: The results of these studies suggest that FDA approved TNFα inhibitors may significantly improve the efficacy of oncolytic virus therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780415PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2015
29 Reads

Publication Analysis

Top Keywords

virus replication
12
tnfα-blocking antibodies
8
infected glioma
8
therapy glioblastoma
8
tumor microenvironment
8
ohsv replication
8
blocking antibodies
8
antibodies evaluate
8
glioma cells
8
tnfα-knockout mice
8
tnfα
7
replication
5
therapy
5
virus
5
vitro coculture
4
ly6c macrophages/microglia
4
amounts tnfα
4
microglia/macrophages test
4
assays infected
4
macrophages/microglia produced
4

Similar Publications